RAYLAPharmaceuticals
Raymed Labs Ltd — Profit & Loss Statement
₹3.83
+0.00%
Raymed Labs Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Tax Rate For Calcs | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Normalized EBITDA | -0.06 Cr | -0.10 Cr | -0.10 Cr | -0.08 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -0.06 Cr | 0.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -0.06 Cr | 0.00 | — |
| Net Income From Continuing Operation Net Minority Interest | -0.18 Cr | -0.10 Cr | -0.17 Cr | -0.08 Cr | — |
| Reconciled Depreciation | 44000.00 | 48000.00 | 54620.00 | 51720.00 | — |
| Reconciled Cost Of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | — |
| EBITDA | -0.06 Cr | -0.10 Cr | -0.17 Cr | -0.08 Cr | — |
| EBIT | -0.07 Cr | -0.10 Cr | -0.17 Cr | -0.08 Cr | — |
| Net Interest Income | -0.11 Cr | 0.00 | -1520.00 | -960.00 | — |
| Interest Expense | 0.11 Cr | 0.00 | 0.00 | 0.00 | — |
| Normalized Income | -0.18 Cr | -0.10 Cr | -0.11 Cr | -0.08 Cr | — |
| Net Income From Continuing And Discontinued Operation | -0.18 Cr | -0.10 Cr | -0.17 Cr | -0.08 Cr | — |
| Total Expenses | 0.59 Cr | 0.10 Cr | 0.11 Cr | 0.08 Cr | — |
| Diluted NI Availto Com Stockholders | -0.18 Cr | -0.10 Cr | -0.17 Cr | -0.08 Cr | — |
| Net Income Common Stockholders | -0.18 Cr | -0.10 Cr | -0.17 Cr | -0.08 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -0.18 Cr | -0.10 Cr | -0.17 Cr | -0.08 Cr | — |
| Net Income Including Noncontrolling Interests | -0.18 Cr | -0.10 Cr | -0.17 Cr | -0.08 Cr | — |
| Net Income Continuous Operations | -0.18 Cr | -0.10 Cr | -0.17 Cr | -0.08 Cr | — |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Pretax Income | -0.18 Cr | -0.10 Cr | -0.17 Cr | -0.08 Cr | — |
| Other Non Operating Income Expenses | 0.53 Cr | — | 0.02 Cr | — | 66000.00 |
| Special Income Charges | 0.00 | 0.00 | -0.06 Cr | 0.00 | — |
| Net Non Operating Interest Income Expense | -0.11 Cr | 0.00 | -1520.00 | -960.00 | — |
| Interest Expense Non Operating | 0.11 Cr | 0.00 | 0.00 | 0.00 | — |
| Operating Income | -0.59 Cr | -0.10 Cr | -0.11 Cr | -0.08 Cr | — |
| Operating Expense | 0.59 Cr | 0.10 Cr | 0.11 Cr | 0.08 Cr | — |
| Other Operating Expenses | 0.37 Cr | 0.06 Cr | 0.05 Cr | 0.03 Cr | — |
| Depreciation And Amortization In Income Statement | 44000.00 | 48000.00 | 54620.00 | 51720.00 | — |
| Depreciation Income Statement | 44000.00 | 48000.00 | 51720.00 | 51720.00 | — |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Cost Of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Amortization | — | 0.00 | 2900.00 | 0.00 | 460.00 |
| Diluted Average Shares | — | 0.42 Cr | 0.43 Cr | 0.43 Cr | 0.43 Cr |
| Basic Average Shares | — | 0.42 Cr | 0.43 Cr | 0.43 Cr | 0.43 Cr |
| Diluted EPS | — | -0.24 | -0.40 | -0.19 | -0.16 |
| Basic EPS | — | -0.24 | -0.40 | -0.19 | -0.16 |
| Net Income Discontinuous Operations | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Write Off | — | 0.00 | 0.06 Cr | 0.00 | — |
| Selling General And Administration | — | 0.02 Cr | 0.02 Cr | 0.01 Cr | 0.01 Cr |
| Selling And Marketing Expense | — | 41830.00 | 16000.00 | 4540.00 | 0.00 |
| General And Administrative Expense | — | 0.01 Cr | 0.01 Cr | 0.01 Cr | 0.01 Cr |
| Total Other Finance Cost | — | — | 1520.00 | 960.00 | 270.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Raymed Labs Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.